"While the BCG vaccine’s presence in the central nervous system is a significant biological discovery, it does not prove it prevents or treats Alzheimer’s. The consistent association of multiple, unrelated vaccines with lower dementia rates continues to puzzle researchers, highlighting the need for definitive clinical trials."
A small but groundbreaking study has provided the first direct human evidence that the Bacille Calmette-Guérin (BCG) vaccine, primarily known for its use against tuberculosis and rarely administered in the United States, can reach the central nervous system of older adults. This finding offers a potential biological explanation for one of the most intriguing and persistent patterns observed in dementia research: the association between certain vaccinations and a reduced risk of cognitive decline. Conducted by researchers at Massachusetts General Hospital, the study, published in Communications Medicine, investigated the vaccine’s impact on immune activity within the brain, a crucial step in understanding its potential neurological effects.
The research, led by Marc Weinberg, involved two parallel one-year, open-label trials with 23 participants aged 55 and older. Of these, 11 individuals exhibited biomarker evidence of Alzheimer’s-related pathology, while 12 did not. Through lumbar puncture, researchers were able to sample cerebrospinal fluid (CSF), the fluid surrounding the brain and spinal cord. Their analysis revealed that the BCG vaccine not only reaches the brain but also demonstrably alters immune activity within this critical environment. While this research establishes biological plausibility, Weinberg was careful to emphasize the study’s limitations: "What we didn’t do is prove that BCG prevents Alzheimer’s," he stated to CIDRAP News, adding that the team also did not demonstrate its efficacy in treating the disease. This crucial distinction underscores the current state of the research: a tantalizing glimpse into a potential mechanism, but far from a clinical recommendation.
The implication of this finding extends to a growing body of research that has observed a statistical correlation between three distinct vaccines – BCG, influenza, and shingles – and lower rates of dementia. While the BCG study itself did not aim to confirm or deny this association, it moved a significant step closer to explaining how such an effect might occur, without yet providing definitive answers regarding prevention or treatment.
Spinal Fluid Evidence from 23 Older Adults
The BCG vaccine, a live-attenuated strain of Mycobacterium bovis, has been a cornerstone of tuberculosis prevention globally for decades, though its routine use in the United States is limited to specific applications, most notably in the treatment of certain bladder cancers. It was within the context of these off-label uses that scientists at Mass General Brigham, including those involved in the current study, began to notice an unexpected trend: individuals receiving BCG therapy appeared to develop Alzheimer’s disease and other forms of dementia less frequently than might be expected.
The current study was not designed to validate this epidemiological observation. Instead, its objective was to investigate a more fundamental question: can the vaccine physically reach the central nervous system, the organ where any protective effect against neurodegenerative diseases would logically manifest? The experimental design involved administering two doses of the BCG vaccine intradermally, one month apart, to the 23 participants. Over the subsequent year, blood and spinal fluid samples were collected. The researchers identified sustained immune reprogramming within the CSF cells, indicating that the vaccine’s influence extended to the brain’s immune environment. Notably, changes in amyloid-beta levels—a hallmark protein associated with Alzheimer’s pathology—were observed. Specifically, amyloid-beta levels decreased in CSF and increased in the blood, but only in participants who did not have pre-existing Alzheimer’s-related changes at the study’s commencement. Those who already exhibited these changes did not show this particular shift.
It is crucial to acknowledge the limitations of this study. With a sample size of only 23 participants and an open-label design without a placebo control group, the findings cannot establish efficacy or benefit. However, what the study does provide is compelling biological plausibility, suggesting a mechanism by which vaccines might influence the brain’s immune landscape.
Higher-Dose Flu Shots and a Sex Difference
Parallel to the BCG research, a separate line of inquiry led by Paul Schulz and his colleagues at UTHealth Houston has been building a compelling case for the role of influenza vaccination in dementia risk reduction for approximately seven years. This investigation was prompted by an unexpected signal identified in their databases by a biomedical informatics team.
Their initial analysis, published in the Journal of Alzheimer’s Disease, compared individuals aged 65 and older who received an annual flu vaccine with those who did not. Over a three-year period, vaccination was associated with a roughly 20% lower risk of developing Alzheimer’s. This protective association strengthened to about 40% lower risk after six years of consistent vaccination, with the effect persisting for at least eight years.
To further refine these findings and address potential confounding factors, such as the "healthy vaccinee problem" (where individuals who get vaccinated are often healthier and more health-conscious overall), the team conducted a more targeted comparison. They compared individuals who received a standard-dose flu vaccine with those who received a high-dose version. This approach helps to mitigate the healthy vaccinee bias because both groups are actively seeking vaccination. In this comparison, published in Neurology and co-authored by Avram Samuel Bukhbinder, the high-dose flu vaccine demonstrated a roughly 15% greater reduction in Alzheimer’s risk compared to the standard dose.
Intriguingly, the researchers also observed that the apparent anti-dementia effect of the flu vaccine lasted for approximately two years, a duration significantly longer than the typical four to six months of influenza protection. Furthermore, their findings suggested that women might benefit more from the high-dose flu vaccine than men. Given that women develop Alzheimer’s approximately twice as often as men, this sex-specific difference is a significant avenue for future investigation.
Three Unrelated Vaccines, One Recurring Signal
Previously, MedicalDaily reported on a study linking the shingles vaccine to a lower dementia risk. This research, led by Daniel Harris of the University of Delaware and utilizing nursing home records and Medicare claims, found a 24% lower relative risk of dementia across more than 500,000 older adults over a four-year period. The study was published in the Annals of Internal Medicine and funded by GlaxoSmithKline, a manufacturer of the shingles vaccine, a disclosure that readers should consider when evaluating the findings.
The critical development since that initial report is not necessarily an increase in the strength of the association, but rather in the consistency and breadth of the evidence. The fact that a shingles vaccine (targeting the varicella-zoster virus), an influenza vaccine, and a tuberculosis vaccine—all designed to combat entirely different pathogens—now exhibit a similar statistical association with reduced dementia risk is a compelling phenomenon.
Researchers have proposed distinct biological mechanisms to explain these observations, varying by vaccine. For the shingles vaccine, the varicella-zoster virus is known to reside in nerve tissue and can potentially replicate in cerebral arteries, thereby increasing the risk of stroke, which is an established contributor to vascular dementia. The proposed mechanisms for influenza vaccination are more varied, centering on the immune system’s potential to either more efficiently clear amyloid plaques or to mount a less aggressive inflammatory response to them.
Glen Finney, director of the Memory and Cognition Program at Geisinger Health, has conceptualized this recurring pattern as "immune retraining." He raises a fundamental question: does this potential benefit stem from vaccines broadly, or is it specific to a particular subset of vaccine types? This question remains open and is a focal point for ongoing research.
Association Is Not Prevention
It is imperative to reiterate a critical caveat: with the exception of the small-scale BCG trials, all the studies described herein are observational in nature. None of them definitively proves that any vaccine prevents dementia. The researchers involved in this work are in agreement that the crucial missing piece of evidence comes from randomized controlled trials (RCTs) that directly compare vaccine administration against a placebo. As previously reported by CIDRAP News, such trials are considered essential for establishing causality.
Conducting these prospective RCTs presents significant challenges. For instance, a recombinant shingles vaccine is recommended for individuals aged 50 and older, and the development of cognitive decline can take many years. This necessitates long-term follow-up periods for participants, which inherently leads to attrition and complicates data analysis.
The "healthy vaccinee problem" also continues to be a consideration. Individuals who are proactive about vaccinations often exhibit a cluster of other healthy behaviors, maintain better connections with healthcare providers, and generally have superior overall health. While statistical adjustments can attempt to account for these confounding factors, they cannot entirely eliminate them. The comparison of different vaccine doses, as seen in the high-dose versus standard-dose flu vaccine study, offers a more robust approach to mitigating this bias than simply comparing vaccinated and unvaccinated groups, but it does not completely resolve the issue.
For individuals and households making decisions about seasonal vaccinations, the practical guidance remains unchanged. Influenza and shingles vaccines are recommended for older adults primarily based on their established efficacy in preventing serious infections, hospitalizations, and mortality. The BCG vaccine, however, is not available for this purpose in the United States, and individuals should not seek it out based on the findings from a study involving just 23 participants.
A prudent discussion with a healthcare provider should focus on eligibility for the recombinant shingles vaccine, the appropriateness of a high-dose or adjuvanted flu vaccine based on age and individual health status, and coverage details under Medicare Part B or Part D. It is not advisable to view these vaccinations as a dementia prevention strategy or to delay essential medical appointments while awaiting the results of trials that may take a decade or more to conclude.
Key Questions Answered
What is genuinely new here? A small trial has demonstrated that the BCG tuberculosis vaccine can reach the human central nervous system and alter immune activity within that environment. This finding was published in July. Concurrently, separate research on flu vaccines has provided a comparative analysis between high-dose and standard-dose recipients.
Do vaccines prevent dementia? No study has definitively proven this. The current research highlights statistical associations observed in observational data, and the researchers themselves emphasize the necessity of randomized controlled trials to establish causality.
Should someone ask for a BCG vaccine? No. BCG is not currently used in the United States for dementia prevention. The study involved a small cohort of 23 individuals and focused on the biological presence and immune effects of the vaccine, not its preventative benefits.
Why do three different vaccines show a similar pattern? The prevailing hypothesis is that vaccination triggers an immune retraining effect that may help reduce brain inflammation. However, the specific mechanisms are thought to differ depending on the vaccine, and none have been definitively confirmed.
Does this change flu or shingles vaccine advice? No. Both influenza and shingles vaccinations continue to be recommended for older adults based on their well-established benefits in preventing serious infections, hospitalizations, and deaths. These recommendations are independent of any potential or speculative effects on dementia risk.
What is the healthy vaccinee problem? This refers to the phenomenon where individuals who choose to get vaccinated often tend to be healthier overall, which can lead to an overestimation of the vaccine’s protective effect when comparing vaccinated and unvaccinated groups. Comparing different vaccine doses, as done in the flu vaccine study, helps to mitigate this bias.
Did women benefit more? In the comparison of high-dose versus standard-dose flu vaccines, researchers reported a greater apparent benefit in women. However, this finding is based on observational data and requires confirmation through further research, particularly in clinical trials.
